Project Data Sphere, an autonomous nonprofit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium, LSC, has just added additional lung cancer clinical trial data to its Project Data Sphere platform – a library-laboratory where the research community can share, integrate, and analyze historical, patient-oriented Phase 3 comparator-arm data to advance research that focuses on improving the lives of cancer patients and their families around the world.
The trial was provided by Eli Lilly and Company and is the seventh lung cancer data set made available on the platform. A total of 3,088 patient lives of data are now accessible for the collective study of aflibercept, bevacizumab, carboplatin, cisplatin, dexamethasone, docetaxel, erlotinib, etoposide, and paclitaxel.
This data addition included 297 patient lives of comparator arm data from the PROCLAIM clinical trial, “Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM),” which studied etoposide, cisplatin, and radiotherapy in patients suffering from non-small lung cancer (NSLC), adding to the almost 30,000 patient lives of data already available through this platform.
More than 1,200 authorized researchers can now access these data sets on the Project Data Sphere platform across core cancer tumor types in addition to the first blood cancer data sets, which have also been recently added. To make sure the full potential of this collection can be realized, Project Data Sphere teamed up with a leader in health analytics and data analysis, CEO Roundtable on Cancer Member SAS, who developed and manages the website and provides registered users of the platform with free analytic tools.
“Eli Lilly, along with other visionary data providers from industry and academia, understand that the pace of research and the probability of new discoveries is significantly enhanced when we share and aggregate clinical trial data,” Dr. Martin J. Murphy, CEO of Project Data Sphere, said in a press release. “We salute all leaders who provide these vital data, for they are a catalyst to cancer research progress. This provides justifiable new hope for cancer patients.”
The Project Data Sphere initiative has been referenced in a series of peer-reviewed papers published in The Oncologist and focusing on prostate cancer research, including collaborations with Sage Bionetworks and the Prostate Cancer Foundation (The Prostate Cancer DREAM Challenge).
The platform was also referenced in several research abstracts which were submitted to the 2015 Annual Meeting of the American Society of Clinical Oncology, along with a series of posters selected for presentation at the recent 2016 Genitourinary Cancers Symposium.
